Exploring factors influencing anxiety and depression
An Exploratory Study Examining Biopsychosocial Markers of Anxiety and Depression
Singula Institute · NCT05466851
This study looks at how different thoughts, feelings, biology, and social support affect anxiety and depression to help improve treatment for those struggling with these conditions.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Sponsor | Singula Institute (other) |
| Locations | 1 site (New York, New York) |
| Trial ID | NCT05466851 on ClinicalTrials.gov |
What this trial studies
This research examines how various biopsychosocial factors, including thoughts, feelings, biology, and social support, contribute to the experiences of anxiety and depression. The study aims to identify why individuals respond differently to treatments and what influences their treatment adherence. It collects a wide range of data, including biological markers, psychological assessments, and social determinants of health, to create a comprehensive understanding of these mental health conditions. By analyzing these factors, the study seeks to improve treatment strategies for anxiety and depression.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 to 65 who meet the DSM-5 criteria for Major Depression or Anxiety Disorders and are willing to participate in clinical treatment.
Not a fit: Patients with serious, unstable illnesses such as severe cardiovascular or respiratory conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more personalized and effective treatment approaches for anxiety and depression.
How similar studies have performed: Other studies have shown promise in using biopsychosocial approaches to understand mental health conditions, suggesting potential for success in this area.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 18 to 65 years of age. * Each subject must have a level of understanding sufficient to agree to all required tests and examinations and sign an informed consent document. * At the initial study enrollment, subjects must have fulfilled DSM-5 criteria for Major Depression, single episode or recurrent. * At the initial study enrollment, subjects may have fulfilled DSM-5 criteria for an Anxiety Disorder Comorbid Psychiatric Disorders, specifically Anxiety Disorders (Panic Disorder, Specific Phobia, Social Anxiety Disorder, Generalized Anxiety Disorder), Obsessive Compulsive Disorder, or a prior diagnosis of Post-Traumatic Stress Disorder, and/or Attention Deficit Hyperactivity Disorder may be enrolled as per assessment and agreement of evaluating clinicians. * Agree to participate in clinical treatment (medication management and psychotherapy) Exclusion Criteria: * Serious, unstable illnesses including hepatic, renal, gastroenterologic, respiratory, cardiovascular (including ischemic heart disease), endocrinologic, neurologic, immunologic, or hematologic disease. * History of head trauma or stroke (also known as a cerebrovascular accident). * Clinically significant abnormal laboratory tests. * Subjects with one or more seizures without a clear and resolved etiology or current use of medication known to lower seizure threshold. * Any use of opioid medication in the past 12 months * Positive HIV test * Current psychotic features or a diagnosis of Schizophrenia or any other psychotic disorder as defined in the DSM-IV. * Subjects with a history of DSM-IV drug or alcohol dependency or abuse (except for caffeine or nicotine dependence) within the preceding 12 months. In addition, subjects who currently are using drugs (except for caffeine or nicotine) must not have used illicit substances or known drugs of abuse in the 2 weeks prior to screen * Subjects who, in the investigator's judgment, pose a current serious suicidal or homicidal risk.
Where this trial is running
New York, New York
- Singula Institute, 353 Lexington Avenue (Room 600) — New York, New York, United States (RECRUITING)
Study contacts
- Principal investigator: Marc S Lener, M.D. — CEO
- Study coordinator: Jen Tung, RN, MA
- Email: info@singulainstitute.org
- Phone: 2125315826
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Depression, Anxiety Disorders, Stress Related Disorder, Biomarkers, Biopsychosocial